MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Total Current Liabilities | ₹1,863 Cr | ₹2,623 Cr | ₹1,353 Cr | ₹1,251 Cr | ₹1,024 Cr |
What is the latest Total Current Liabilities ratio of MANKIND PHARMA ?
Year | Total Current Liabilities |
---|---|
Mar2023 | ₹1,863 Cr |
Mar2022 | ₹2,623 Cr |
Mar2021 | ₹1,353 Cr |
Mar2020 | ₹1,251 Cr |
Mar2019 | ₹1,024 Cr |
How is Total Current Liabilities of MANKIND PHARMA Trending?
Years | Total Current Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹1,863 Cr | -28.98 | |
Mar2022 | ₹2,623 Cr | 93.84 | |
Mar2021 | ₹1,353 Cr | 8.21 | |
Mar2020 | ₹1,251 Cr | 22.13 | |
Mar2019 | ₹1,024 Cr | - |
Compare Total Current Liabilities of peers of MANKIND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MANKIND PHARMA | ₹83,865.6 Cr | -6.5% | -7.6% | 57% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹367,470.0 Cr | 2% | -0.3% | 59.8% | Stock Analytics | |
CIPLA | ₹112,990.0 Cr | 6% | 2.8% | 50.4% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹105,846.0 Cr | 2.6% | 7.9% | 94.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹103,849.0 Cr | 3.7% | 5.8% | 17.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹96,742.1 Cr | -1.3% | -2.8% | 31.5% | Stock Analytics |
MANKIND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | -6.5% |
-7.6% |
57% |
SENSEX | 1.7% |
0.7% |
19.2% |
You may also like the below Video Courses